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Abstract
Background: The role of community pharmacists is changing globally with pharmacists engaging in more
clinically-oriented roles, including in mental health care. Pharmacists’ interventions have been shown to improve
mental health related outcomes but various barriers can limit pharmacists in their care of patients. We aimed to
explore the experiences of people with lived experience of mental illness and addictions in community pharmacies
to generate findings to inform practice improvements.
Methods: We used interpretive description methodology with analytic procedures of thematic analysis to explore the
experiences of people with lived experience of mental illness and addictions with community pharmacy services.
Participants were recruited through multiple mechanisms (e.g., paper and online advertisements), offered honorarium
for their time, and given the option of a focus group or interview for participation in our study. Data were gathered
during July to September of 2012. Interviews and focus groups were audio-recorded, transcribed verbatim, and
analyzed by two researchers.
Results: We collected approximately nine hours of audio data from 18 individuals in two focus groups (n = 12) and six
individual interviews. Fourteen participants were female and the average age was 41 years (range 24 to 57 years).
Expectations, decision-making, and supports were identified as central themes underlying the community pharmacy
experiences of people with lived experience of mental illness and addictions. Eight subthemes were identified
including: relationships with pharmacy staff; patient’s role in the pharmacist-patient relationship; crisis and triage;
privacy and confidentiality; time; stigma and judgment; medication-related and other services; and transparency.
Conclusions: People with lived experience of mental illness and addictions demonstrate a high regard and respect for
pharmacist’s knowledge and abilities but hold conservative expectations of pharmacy health services shaped by
experience, observations, and assumptions. To some extent, expectation management occurs with the recognition of
the demands on pharmacists and constraints inherent to community pharmacy practice. Relationships with pharmacy
staff are critical to people with lived experience and influence their decision-making. Research in the area of
pharmacists’ roles in crises and triage, especially in the area of suicide assessment and mitigation, is needed urgently.
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Background
Pharmacists have been identified as playing important
roles in primary mental health care as part of the
primary mental health care team [1]. The enhanced roles
for pharmacists in mental health care are increasingly
clinically-oriented, collaborative roles, [2] in keeping
with current standards of practice, and offer opportun-
ities to improve gaps in the mental health system related
to effectiveness, efficiency, and equality of care [3, 4].
Professional role revision in the health system can also
help to meet public demands and changing expectations
[5]. Public expectations of pharmacists, who are trusted,
accessible, and in frequent contact with the public [6–8]
have been evolving with recognition that pharmacists
have roles beyond the “drug expert” [9]. Understanding
the public and patients’ perspectives on pharmacy
services is important, especially with changes in roles, in
order to help inform how and under what circumstances
pharmacists can efficiently and effectively collaborate in
providing services to people with lived experience of
mental illness and addictions. Although existing research
and policy documents indicate positive impacts of
pharmacists’ roles in mental health care [1, 10], there are
also findings of significant barriers (e.g., privacy, stigma,
limited staffing) that restrict pharmacists in their care of
patients with mental illness and addictions [11–21].
There is limited knowledge on how these various chal-
lenges and opportunities in pharmacy practice impact
patients with mental illness and addictions in their expe-
riences of pharmacy services. Surveys [13, 14, 22, 23]
have been conducted and primarily focused on descrip-
tive statistics regarding the nature and range of phar-
macy services offered, and other constructs including
stigma and self-reported satisfaction. Few qualitative
studies regarding patients’ experiences with pharmacy
services have been conducted [19, 24]. For example,
Knox et al. conducted computer-assisted telephone
interviews with 210 Australian people regarding their
experiences, expectations, and satisfaction with technical
and functional quality of community pharmacy services
for people living with and/or caring for someone with
lived experience of mental illness [19]. Technical quality
was assessed using self-reported perceptions of wait
times, receipt of verbal and written advice, and if
received, the characteristics of the content. Functional
quality was assessed based on self-reported satisfaction
with interactions and perceptions of services including
what was desirable and areas for improvement. Data
were gathered based on an instrument with 48 rating
scales, 38 multiple-choice checklists, and 19 open-ended
questions, which included thematic analysis through a
framework for patient-centred care. Participants desired
efficiency, consistent, and personalized pharmacy
services. Issues with technical service delivery and
experiences of stigma were reported as undesirable and
an area requiring improvement [19]. Treloar et al. [24]
reported findings of a thematic content analysis of inter-
views with 25 methadone clients in Australia, of whom
21 received takeaway doses from pharmacies. Partici-
pants indicated that trust in the relationship with phar-
macists was important with takeaway dosing and helped
to provide encouragement for patients. Accessing daily
methadone doses presented both conveniences and
inconveniences for many participants. Studies such as
these demonstrate that a host of factors (e.g., inefficien-
cies, information quality, privacy and confidentiality, and
stigma) can influence experiences of people with mental
illness and addictions in community pharmacy settings.
Literature is also available describing patients’ perspec-
tives and expectations of pharmacy services generally
[25], within the umbrella of chronic conditions [26, 27],
or more recent pharmacist-delivered public health initia-
tives [9] (e.g., smoking cessation [28], alcohol screening
[29–31]). These studies contribute additional knowledge
regarding the patient experience in general, including
information on preferences for services, relative import-
ance of services offered, and willingness to engage in
services, but more research specifically examining the
perspectives of people with mental illness and addictions
in pharmacy contexts is needed to inform practice and
systems’ improvements. This is especially important in
this group of people given established issues with accessibil-
ity of care, inequalities in health care service delivery, and
poorer health outcomes affecting this population [32–41].
To contribute to the knowledge in this area, we con-
ducted a qualitative study to explore the experiences of
people with lived experience of mental illness and addic-
tions, or their support people or caregivers, with commu-
nity pharmacy services. The goals of conducting this study
were twofold: to explore and understand the experiences of
people with lived experience of mental illness and addic-
tions when receiving community pharmacy services; and to
generate new findings that can inform interventions for
practice that are underpinned by a behaviour framework
[42] to help pharmacists improve their care of people with
lived experience of mental illness and addictions.
Methods
Design
We used interpretive description methodology [43], with
analytic procedures of thematic analysis [44, 45] to ex-
plore the experiences of people with lived experience of
mental illness and addictions with community pharmacy
services. Interpretive description methodology was ap-
propriate for our goals for reasons including our
acknowledgement of the socially constructed element of
human experience and that these experiences are part of
multiple constructed realities [43]. This methodology is
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in keeping with the theory and models of behaviour that
influenced our work through the research process in-
cluding Role Theory [46], the Theoretical Domains
Framework [47], and the Behaviour Change Wheel [42].
Our intention in studying this phenomenon was also
pragmatic with the goal of using the findings to inform
future intervention development for practice-based im-
provements in mental health care, which is in keeping
with interpretive description [43].
Study participants
We used convenience sampling and recruited people
with lived experience of mental illness and addictions,
and their caregivers, herein abbreviated and referred to
as PLEs for brevity, using multiple mechanisms includ-
ing advertisements in public places (e.g., libraries, gro-
cery stores), pharmacies, health clinics, Internet-based
classifieds (e.g., Kijiji.ca), and word-of-mouth. We were
conscious of potential difficulties in recruiting partici-
pants and used existing literature regarding mechanisms
to improve recruitment of potentially vulnerable or mar-
ginalized groups [48–52]. Inclusion criteria were that
PLEs had to be able to understand and speak English,
have experience with community pharmacy services for
mental illness and/or addictions, such as with obtaining
prescription medications, and at the time of the interview
or focus groups, be considered as community-dwelling
(i.e., not a resident of an institution). Recruitment oc-
curred during June and July of 2012. Interested PLEs were
offered the option of interviews or focus groups. We ac-
knowledged that there are inherent differences and poten-
tial benefits and limitations with using both methods of
data collection. However, our rationale and approach was
informed by others conducting qualitative research with
PLEs [53]. Some participants prefer face-to-face or tele-
phone interviews depending on their cognitive abilities
and comfort, and for others this method resembles the
clinical encounter and therefore can distort the informa-
tion that is shared [53]. Participants were paid a one-time
honorarium of $20.00 (cash given at the interview or focus
group) for participation.
We established a stopping criterion for data saturation
[54] of eight to ten participants with the inclusion of three
to five additional participants with no new information
occurring. In interpretive description, and as indicated in
the work of Thorne [43], the concept of saturation can be
“highly problematic” (p.98), depending on the question, if
researchers presume to have obtained sufficient data to
understand all that is relevant about a clinical phenomenon,
and in the case of our study, the experiences of people with
mental illness and addictions in the community pharmacy
context. However, we attempted to place a boundary on the
potential size of the sample that was sound in principle and
from a methodological perspective.
Data collection and analysis
A semi-structured interview guide was developed
(Additional file 1) based on our knowledge of the
literature, our clinical experiences, and our study
goals. The guide was reviewed by the members of the
research team, refined, and revised based on feedback.
The guide was then pilot-tested with four senior
pharmacy students, a medical student with a Masters
degree and research background in mental illness and
addictions care, and two community pharmacists.
Background information regarding the project’s pur-
pose and objectives was explained prior to the exam-
ination of the guide for understandability, relevance,
clarity, and fitness for purpose.
All interviews with participants, collected during June
through September of 2012, were digitally audio-recorded,
and subsequently transcribed verbatim. Field notes were
written after each encounter. All transcription data were
stored, organized, and coded with the use of QSR NVivo
10 [55]. We (ALM, DMG) followed procedures outlined
for thematic analysis [44, 45]. The analysis stages included
[44, 45]: familiarizing ourselves with the data through
reading the transcripts along with the audio several times
to develop “a sense of the whole beyond the immediate
initial impression”(p.143) [43]; generating initial codes
inductively with open coding and “flagging” data elements
we thought were meaningful as we analyzed transcripts
[43]; searching for themes, reviewing themes, defining and
naming themes through bringing coded data together and
“interrogating” [43] relationships among codes and
themes. In the initial analysis stages, QSR NVivo 10 tools
including word frequency queries and dendograms (i.e.,
depicting cluster analysis with codes by word similarity)
were used [55]. Initial coding was conducted independ-
ently at first and subsequently over the course of ten, one
to two-hour meetings, codes and theme development
were refined, debated, interrogated, and finalized. To
reduce bias and enhance confirmability, we used
approaches such as analytic memo writing and engaging
in discussions about our own subjectivity during data
analysis as part of our audit trail. We also included all
members of the team to review and critique the interpret-
ation of the findings.
Results
We collected approximately nine hours of audio data
from 18 individuals using two focus groups of eight and
four participants, respectively, and six individual inter-
views. The second focus group was scheduled for eight
participants, but four did not attend. One person had an
unexpected scheduling conflict and the other three
could not be reached in follow-up.
Fourteen participants were female and the average age
of participants was 41 years (range 24 to 57 years). All
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participants reported living with mental illness and some
also indicated that they cared for others with mental
illness and addictions either through employment or
personal connections. We did not ask participants to
specifically disclose their mental illness diagnosis or their
medications. However, three people self-reported having
addictions with one person reporting tobacco as the sub-
stance of their addiction. Participants had some difficulty
estimating their visit frequency to pharmacies for health
care-related needs. This was in part due to the changing
nature of their health status, which varied the frequency
of visits, and because they often went to pharmacies for
other reasons (e.g., food items, personal hygiene prod-
ucts). With these considerations, estimates of visits to
the pharmacy for prescriptions for mental health needs
ranged from twice weekly to every three months. Two
people (one from each focus group) reported not always
using the same pharmacy for prescription-related needs.
Three PLEs in the focus groups reported being uncertain
of whether they were satisfied with their pharmacists’
services and two interview participants reported dissatis-
faction with pharmacy team members as a reason for
switching pharmacies, which resulted in better satisfac-
tion at the new pharmacy.
Themes: Expectations, decision-making, and supports
We represented the product of our interpretive descrip-
tion of PLEs experiences with community pharmacy
services in a metaphorical representation of the data,
and within this, a modified Venn diagram [56] (Fig. 1).
There are central elements to the experience of PLEs in
accessing and receiving community pharmacy services,
Fig. 1 Representation of the experiences of people living with mental illness and addictions with community pharmacy services
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which include expectations, decision-making, and sup-
ports. Eight subthemes are linked among these overarch-
ing umbrella themes.
As depicted in Fig. 1, decision-making by PLEs in the
pharmacy context was influenced by eight subthemes
that centered on expectations. At the base of the experi-
ence were the supports (relationships, money, employ-
ment, health services, information), depicted as the
fertile (or infertile) ground. These symbolized many
required ingredients for health and wellness. These sup-
ports were critical to PLEs’ capabilities and opportunities
with engaging in decision-making. The length of the
stem is used to represent the amount of distancing
between community pharmacies and the other supports
for patients. A short, strong stem represents a well-
integrated and connected community pharmacy and a
long stem indicates a more isolated pharmacy that is
disconnected from the community’s services and needs.
The Venn diagram configured as the plant’s flower dem-
onstrates the linkages among expectations and subthemes.
The experiences of participants within each subtheme
often overlapped and fed directly into reconstructing the
PLEs’ expectations of pharmacy services and subsequently
influenced their decision-making.
The majority of PLEs in our study expressed high
expectations of pharmacists’ services compared to what
they typically received, with several participants, but not
all, being aware of or having experienced the full range
of pharmacists’ capabilities. Participants’ expectations
were in keeping with the pharmacists’ standards and
scope of practice, ranging from those well within
minimum standards of practice (e.g., technical aspects of
dispensing) and those that would be considered more in
keeping with clinically-oriented, patient-centred stan-
dards of practice (e.g., supporting patients with research
literature and its interpretation for decision-making).
Because of this, the decision-making process around
medications and health-related concerns for PLEs was
not always ideally supported. Participants also sought
out different pharmacies when their expectations were
not met, despite resulting inconveniences (e.g., travel)
for some PLEs. Other participants accepted that their
expectations would not be met based on rationalizations
about the restrictions on pharmacists in practice (e.g.,
other demands on the pharmacist’s time).
Subthemes
Relationships with pharmacy staff
Relationships that were built with pharmacists were
important in the PLEs’ experiences and were viewed as
an essential support in making decisions. For some
PLEs, the linkages with pharmacists were critical in their
mental health care as some other professionals were
inaccessible, including prescribers.
“ (Focus group 2, respondent 9; FG2R9) … my
psychiatrist is only in once a week or twice. … He
only books to see me every 4 months. … when I go
to see him, he refills for the next year. … last
spring, he gave me enough refills to get me through
to next March. FG2R11: Wow! FG2R9: … I was
only in there less than 5 minutes. It’s kind of
ridiculous that he can … that he’s giving me refills
until, like, the next year. It’s like it just seems a
little absurd. … I don’t have a problem with it
really but it’s kind of not really appropriate. And I
find I rely on the pharmacy more than I rely on my
own psychiatrist because he’s not there. … as soon
as my psychiatrist does anything different, I hear
from the pharmacy. Directly after, everything goes to
the pharmacy. So as soon as something goes through to
them, they’re always calling me and making sure that,
you know, I know all the new changes.”
Another PLE discussed her experience with and pref-
erence for working with a pharmacist with whom she
had developed a good relationship. She spoke of her
willingness to engage and share with this pharmacist,
whom she trusted and respected, in contrast to the other
pharmacists at the same location:
“There’s one lady that is wonderful. She is. I could talk
to her about anything. And she has gone to the end of
the earth to get me help. Like at Christmastime, my
drug plan for some reason just decided not to work,
and I needed it [medication]… badly over the holidays.
And she went to bat. She got everything ironed out like
two days before Christmas. And she really, really,
really went to bat for me. … But she’s one of maybe 6
people that work there. And I don’t have that same
degree of comfort. So when she’s not working, I
basically don’t even really talk about the medication
with them. I just pick up my prescription and go on
my way.” (Focus group 1, respondent 1; FG1R1)
Another focus group participant described going to
two pharmacies, one for food items, out of convenience,
and one for her prescriptions, based on her long-
standing relationship with the pharmacist:
“I actually go to two pharmacies. I go to [pharmacy X]
for like my groceries and I have a … [pharmacy Y], I
know the man who runs the one out in [location]. …
He’s really nice. I go there for my
prescriptions.”(FG1R5)
One PLE described using the pharmacy and pharmacy
staff as an important part of her primary care health care
because they knew her and her medications:
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“I mean that’s where I go if my knees hurt or I have a
cough or anything like that. I go to the pharmacy. …
You see your doctor when you can or when the
pharmacist says you need to see your doctor or
whatever. But I think often it’s a first point of
contact … ” (Interview Respondent 1; IR1)
Another PLE demonstrated through her example that
strained relationships can occur with some, but not all
members of the pharmacy team, after she had an intense
argument with technicians regarding her medication in-
surance not working while processing a prescription:
“I’ll be hesitant to fill a prescription after the run-in with
the last two technicians. But when I see my regular
pharmacist, I’m okay.” (FG2R12)
For one PLE, several difficulties occurred in the
relationship with her pharmacist but she felt unable to
confront him and did not perceive she had a mechanism
for providing the feedback. This significantly limited
here relationship with the pharmacist:
“Well, in particular, the pharmacist that I go to is very
closed. … as far as their body language. So it’s not very
easy to go to the person and speak to the person and
talk to them.” (IR2)
Patient’s role in the pharmacist-patient relationship
Some PLEs saw their own role in the relationship
with their pharmacists as quite limited or had never
considered it. Those that were able to discuss their
role included descriptions of honesty or lack of
disclosure, and most discussions related to medica-
tion supply. The patient’s role in the relationship
depended on the quality of the relationship with the
pharmacist.
In one focus group, participants discussed the need for
honesty and communication in order to receive help:
“FG2R3: You have to be honest with them. If they
don’t know what’s going on, they can’t help you. Just
like with your family doctor, if you don’t let them
know, they can’t do anything. … FG2R2: …
Communication is the key. Honesty is within that. Yes.
So you have to be an advocate for yourself. FG2R1:
That’s for sure. FG2R2: … Because nobody else can or
would. FG2R: Yes. [group agreement] FG2R5: I guess
this falls into the same – don’t die of embarrassment.
… talk to somebody if there’s a medical issue, no
matter how embarrassing it might be going on. Maybe
there’s something the pharmacist could do to help. But
if they don’t know, they can’t help you. You’ll still
suffer with it.”
One PLE with self-harming events associated with medi-
cations discussed disclosing the information openly after
switching pharmacies and experiencing better relationships:
“… I feel like I should be honest with what happens …
I think the pharmacist before [at other pharmacy] was
… I would say something other than that I overdosed.
I’d say something like, “Oh, I lost my meds,” or
something like that. And it was just in response to not
wanting them to judge me … obviously they probably
knew anyways. … they’re genuine with me and so I’m
straightforward with them [new pharmacists]. … I
don’t like having to like feel that I have to hide what’s
going on. … I mean the fact that they’re willing to be
… straight … That they’re comfortable with it is a big
relief. … it would just feel silly to not be honest.” (IR6)
Crisis and triage
Some participants discussed crisis and suicide assess-
ment as a role for pharmacists. Situations were discussed
in which patients had used medications in suicide at-
tempts. In one situation, the PLE discussed that she was
uncertain as to whether the pharmacists knew she had
used medications as the means to attempt suicide
despite having a significant hospital stay and being
dispensed small quantities of medications following
the attempt. Despite some trepidation regarding feasi-
bility, she supported pharmacists’ training in suicide
prevention:
“… I have a really good relationship with him [doctor].
And I think that it’s important to have that type of
relationship with your pharmacist, that they know you.
… and they could say, “Is everything alright? Is there
something you want to talk about?”… There’s a course
before the ASIST*course. … SAFE-T†, that’s what it is!
That’s the first one and then the ASIST is the second.
… SAFE … to kind of recognize what’s happening and
to get help. … So you know, to call [crisis service] or to
call their psychologist or psychiatrist or something and
make that connection and get them that help. … they
[technicians] could even go to the pharmacist and say,
you know, “[Participant] seems really off today,” or,
“She didn’t come in and pick up [her prescription]” …
Or anything, anything that they happened to notice
about how you’re feeling or talking. So if they kind of
have that awareness. In my mind, it’s better to be safe
than sorry in terms of going to somebody and saying …
or to ask your customer really how they’re doing. …
And how much, as a pharmacist, do you want to take
on? Do you want to become a mental healthcare
worker at the same time? Although, I do believe that
everybody in the healthcare sector and the public
should have some suicide prevention training.” (IR1)
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*Applied Suicide Intervention Skills Training; † Suicide
Assessment Five-Step Evaluation and Triage.
One participant nonchalantly described using the
pharmacy as a resource for a range of things from
culinary conveniences to a mental health crisis:
“Usually it’s just for getting meds honestly. I mean it’s
like a minute from my house so we get like staples
there too, milk or whatever. I don’t know, sometimes
I’ve had to go and ask like for their advice whether I
should continue taking a med. Basically I sometimes
overdose on my meds. And then it’s like okay, “well,
when should I start taking my other meds?” (IR6)
This participant also suggested roles in keeping with
the pharmacist’s scope of practice with populations such
as university students:
“… that would be an awesome job of a pharmacist.
… if someone is just on like a mild dose of
antidepressants and they seem to be getting worse,
it’s like they [pharmacists] should be able to point
them in the direction of resources so that you don’t
have a major episode. Because once you have an
episode, it’s much more likely that you’ll have
another episode.”
Privacy and confidentiality
Privacy and confidentiality was an expectation by PLEs
but several examples were shared in which this had not
been afforded and this was a barrier to discussing
medication-related issues. All participants discussed
ideas regarding the use of private counseling rooms,
albeit some participants were skeptical due to time
restraints. Telephone conversations with pharmacists
were frequently offered by participants as solutions to
overcoming privacy in the pharmacy environment:
“… having rooms to go in and discuss your drugs or
having lots of access, you know, on the phone to talk
about personal drug concerns… Instead of having to
discuss it there with everybody standing there … is not
so great. … If they could have that, it would be good.
But it doesn’t sound reasonable unless they had a
pharmacist just to do that. I think they would almost
need that. … Interviewer (I): How do you feel about
that [having medication discussions at the pharmacy
counter]? IR5: A little intimidated. Other people
standing there looking at you, listening. [laughs] … It
is quite intimidating. I: In that situation, are you able
to discuss what you need to discuss when you’re feeling
that intimidation? IR5: Not always. But you know,
there’s always the phone. You can always have the
conversation on the phone if you need to. Right?” (IR5)
Time
Some participants did not expect pharmacists to have
time for discussing medications or other concerns.
Issues with limited staffing were identified as one of
several contributing factors impacting the pharmacists’
workloads:
“I find there are not enough pharmacists. … there’s
maybe one or there might be two if you’re lucky. But
there should … be more of them because sometimes
you can have … a couple of people with some complex
problems in line, and you’re waiting, and waiting, and
waiting, and waiting. It’s not particularly that
pharmacist’s fault, it’s just that whoever is hiring them
just didn’t hire enough pharmacists. It would be nice if
there were like 2 or 3 of them.” (FG1R5)
The manifestations of pharmacists under time pres-
sure (e.g., running from task to task) formed the identity
of pharmacists for some PLEs:
“… the pharmacist at the place that I go is running.
It’s the lady who’s running. You know, she seems to be
running a lot. … [group laughter] … she seems really
busy.” (FG1R1)
Another PLE discussed the how “busy” the pharmacist
was and that the use of the private counseling room
given the time constraints would yield the pharmacist as
inaccessible:
“… They’re so busy now. If they had to go to a room,
they would be in there forever.” (IR5)
In discussing time constraints, some participants com-
mented on the greater time spent with their pharmacist
versus their doctor:
“… they [pharmacists] spend more time with us. So
they do know more about what’s going on and how
we’re being affected by the medications … maybe
they’re not specifically trained like a doctor but I’ve
been in the doctor’s office for two minutes. … you
often spend a bigger chunk of time talking to the
pharmacist about what’s going on and relaying
symptoms and different things that could occur,
reactions with other medications. I think in some
ways they [pharmacists] probably are a better
advocate just because they do know you more. They
see you more. … ” (FGR12)
One PLE discussed being mindful of pharmacists’
and technicians’ time and purposefully went straight
to the pharmacist with questions, regardless of the
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issue. This was perceived to be more efficient and in
their experience, the pharmacists were accessible and
made time for them:
“I always ask for the pharmacist because why go
through the middleman [technician]? … And there’s
two main pharmacists where I go. And both will take
time. I don’t need to make an appointment to talk to
them, and they don’t seem to rush me. And my doctor
doesn’t rush me either. And they’re connected in the
same building, which is nice.” (FG1R2)
Stigma and judgment
Several participants discussed stigma and judgment, with
contrasting experiences and outcomes. Some people
who experienced stigma were anticipatory of its recur-
rence and this altered how they interacted with pharma-
cists. Several participants chose to switch pharmacies or
proactively interact with only selected members of the
pharmacy team for services. This resulted in significant
travel and other inconveniences for PLEs:
“ … they didn’t mean for me to hear that but I could
hear in the background, the pharmacist yelling, “…
Just get her off the phone. She’s one of “those”
[participant emphasis] people.” … they treated me like
I was a bother. … I remember they short-changed
my pills … and I could hear somebody talking in
the background, “Oh, she’s mentally ill. Don’t take
her too seriously.” [strong group reaction with gasps]
… that was it! So I was just like, “you know what, I
can get my drugs somewhere else”. And I switched
from then on. … When he [another pharmacist]
opened up a pharmacy, I’m like, “I’m coming to you
because you’d never treat me like that!” … I know I
could ask him … anything, and he doesn’t judge or
he doesn’t get uncomfortable.” (FG1R5)
A PLE expressed fear and anticipated judgment by
pharmacists related to overdose with medications but
was received with support:
“… at the pharmacy I’m at now … I’d gone in before
being like, “I overdosed and this is what is happening”
sort of thing. So they know that. … they know my
name and they ask me how I’m doing. You know, it
makes a difference. … And I was really nervous the
time after that going back in and being like, “oh my
God, they’re going to judge me”… . But I mean no,
they’re pretty good”. (IR6)
Medication-related and other services
Participants inherently expected pharmacists to fulfill
duties related to medications including provision of
information as a part of routine services, but for some
PLEs this was limited to initial medication education in
which they were told information such as side effects
and how to take the medication. Overall, there was
limited information sharing in the pharmacist-PLE rela-
tionship and when it did occur, it appeared mainly
focused on drug interactions and side effects. For many
PLEs, activities such as dropping off prescriptions and
picking up refill medications occurred primarily with
technicians. Although there was a connection and
rapport with a pharmacy team member for a “chat”,
additional follow-up for sharing of clinical information
with the pharmacists would have occurred only if the
technician perceived a need based on the discussion with
the PLE:
“No, more time I think with the technician. … And
there’s a couple at the drugstore that I go to. … they
know me by my first name. And we chat and joke a
bit, and that kind of thing. … And you know, bits
about your personal life. … And I think personally
that I might be more inclined to chat with them or
tell them because I seem to have a more personal
relationship with them. …” (IR1)
Other PLEs viewed that pharmacists should be more
engaged when patients are picking up refills:
“I think they should ask you how you are doing
because usually you see a pharmacist more often than
your doctor. You’re going in at least once a month to
pick up your pills. They should say, “How are you
doing with that anyhow? Any changes?” Because they
can be sort of your frontline. Like they might pick up
something that’s wrong even before your doctor does,
just because they see you so often. [group members
agree]” (FG1R5)
Most PLEs described a desire for more information to
support their decisions regarding medication treatments.
They were interested in pharmacists helping them access
and interpret research relevant to their illness and its care.
They indicated that they would like to see pharmacists
proactively anticipate their information needs:
“FG2R1: … anybody that could find me a study that
says … the random whatever that double blind study
is on that particular drug, and they gave 50 % a
placebo and the other this, and this is the percentage
of people that actually improved being on that drug. I
would feel a whole lot more comfortable knowing that
that particular scientific study is in place. And if the
pharmacists can tell me that, that’s great. FG2R2:
That’s what my doctor has done, like when I’ve been
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asking questions. Because there was a new medication,
because I was newly diagnosed in the spring, and he
pulled up case studies and then he gave me the
reference. He read, you know, the highlights when I
was in the doctor’s office but then he gave me the
information and then I read it thoroughly myself at
home on the computer too. … It can be results but
unless they’re statistically significant, it doesn’t really
count. … FG2R5: I like to have the evidence in hand. I
don’t just take somebody’s word for it. … I want to see
like an actual study. Because it’s my body and brain
I’m putting on the line, I want to be sure that there
was research done on it and what I’m taking isn’t
dangerous, and there was actual quantitative results,
something that could be measured. FG2R7: But can’t
you seek that information on your own? FG2R5: You
can but it’s hard because oftentimes when you look up
a scientific paper, you have to pay for that paper.
FG2R1: [interrupts and agrees] …. “the medical
libraries” [participant emphasis]… FG2R5: You have
to subscribe to the website or you have to pay for that
paper. They’re not cheap. Sometimes they can be $25,
$35 for that paper. FG2R1: If you can even get
[participant emphasis] access. FG2R5: But sometimes
pharmacists do have access. R: Yes [group agreement].
FG2R2: And they have more specific information on-
hand so they can help you leaf through that. So then
you can go in and select what you want to read. [long
pause] Again, they have a wealth of information, and
they need to be able to share it with you, particularly
when you ask, and you shouldn’t even have to always
ask, they should know sometimes to give you the
information when you don’t know necessarily the question
to ask. Because some people don’t or won’t.”
Other PLEs similarly discussed using multiple sources
such as health care professionals, including telephone
conversations with pharmacists, and the Internet:
“IR3: I use the Internet. I talk to the doctors, talk to the
pharmacists. That’s the main sources. I: Do you have
any favourite Internet sites? IR3: NIH, Mayo Clinic. …
Like I say, I think that we definitely see pharmacists as a
source of information. … how many people make use of
that, I don't know. I would if I didn’t have my family
doctor. I do go and ask questions and call and harass
them [pharmacists]. Maybe that’s why they know my
first name. [laughs]” (IR3)
Transparency
Transparency issues manifested from two key areas in
the context of pharmacy practice for PLEs: 1) issues
with respect to the communication and clarity in
medication procurement, preparation, record keeping,
and payment processes; and 2) conflicts of interest
with products or medications (e.g., linkages with
pharmaceutical industry).
A lack of transparency regarding the business implica-
tions for a pharmacy procuring a relatively expensive
medication left one participants feeling frustrated and
stigmatized:
“I had to get actually my psychiatrist to speak to her
[pharmacist] about that because she was sort of
chastising me because I was on this expensive drug. And
indirectly, like non-verbally, like, “Oh, you know, that’s
really expensive, you know. Like you’ve got to call and
tell us. You know, that’s a special order.” And she kept
saying how expensive it was. You know, implying that I
shouldn’t be taking it. … And also one of the people that
worked at the service desk [in the pharmacy] when I
was getting a purchase order for an over-the-counter
[medication] that had to go through the drug store, he
sort of had the same opinion. … they know you’re on
social assistance if you get a purchase order because
they’re familiar with the process. And so it’s kind of like
you’re less of a person if you’re on social assistance even
though you’re working part-time and maybe hopefully
in the future, you’re going to be working more and off the
system, you know. … So they put you in a category … a
lot of people … think people on social assistance sit home
and drink beer all day. You know, a lot of people think
that.” (IR5)
Questions and lack of clarity around dispensing proce-
dures were demonstrated through a discussion on a
commonly occurring phenomenon in pharmacy practice
in which generic manufacturers are changed from one
prescription to the next depending on which brand is
currently available at the pharmacy. Participants had
identified that they noticed the changes in brands, which
was a source of confusion regarding why brands were
changing and without proper communication from the
pharmacy to the PLE:
“FG2R4: It will be like APO-sertraline and the next
one will be… FG2R8: Mylan or whatever. FG2R4:
Mylan. … Yes, I notice on the bottle, there’s al-
ways… It’s a generic. FG2R5: It’s just depending on
who made that. Apotex is one manufacturer … the
name before the dash is who makes it. FG2R8: Yes.
I just figure like if you’ve been on the same one for
a long time, and they use different manufacturers
sometimes, they might want to check with people
more often and see if they’re still doing okay when
they have different manufacturers. FG2R5: Yes.
Because they’re supposed to be the same but they’re
not at times. FG2R8: Yes, because I’ve noticed I’ve
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felt different sometimes … or different side effects
and things like that.”
Transparency also became an issue when exploring
roles for pharmacists in doing education sessions for the
public. Participants discussed potential concerns regard-
ing conflict of interest vis-à-vis the pharmacists’ roles in
dispensing medications:
“FG1R11: … if education sessions are like run by like
pharmacists then it kind of just raises a red flag
because everyone is just so wary of … the
pharmaceutical industry with…. like all the money
involved in pushing drugs. Like I think that maybe it
should be run by someone who doesn’t have so much
like financial interest in drugs, I guess. FG1R10: Yeah
… or maybe pharmacists with some other types of, you
know, psycho-social interventions of some kind could
combine and talk together. And definitely not a drug
rep. [group laughter]”
Discussion
Our interpretive description study is one of a few quali-
tative explorations of people with mental illnesses and
addictions and their experiences with community phar-
macy services. As such, it provides useful information
that will inform intervention and program development.
The flower, as our visual representation of the interpret-
ive description for people with lived experience of
mental illness, can be used when developing, implement-
ing, and evaluating service development, making policy
changes, and developing education and training oppor-
tunities for the pharmacy practice context. Importantly,
our findings suggest that there is recognition and poten-
tial support for pharmacists’ roles in mental health care
by the public to be “points of first contact” with the
health system, more involved with facilitating informed
decision-making, and equipped to participate in suicide
risk assessment and mitigation.
Participants’ expectations of services were often higher
than what was offered, which would be described as
minimum standards of practice in many examples
shared. Participants accepted, adjusted, and lowered ex-
pectations given their assumptions, experiences, and ob-
servations of pharmacists in the practice environment.
Various barriers such as limited staffing, lack of privacy,
and undeveloped/inadequate rapport, including issues
with stigma, led many participants to rationalize not
having expectations met in the pharmacy settings. Sev-
eral people chose alternative mechanisms in how they
interacted with pharmacists, such as using the telephone
for talking with the pharmacist at a different time about
their questions or concerns, and being selective in which
pharmacist or pharmacy they chose. Interestingly, similar
barriers (e.g., stigma, time) to the implementation of
mental health services have been reported in studies
examining perceptions of pharmacists and pharmacy staff
[12, 20]. Based on our results, significant challenges in the
pharmacist’s context of practice exist and impact
pharmacist-PLE relationships. In order for pharmacists to
ideally practice to their full scope in mental health care, as
suggested by various organizations and policy documents
[1], and even many participants in our study, adjustments
in the structures and processes in the work environment
are required.
Relationship quality between PLEs and pharmacists, and
for some participants with technicians, was paramount.
The quality of the relationship was imperative for infor-
mation sharing and open communication around health
and medications. There were several participants that
disclosed information to pharmacists only out of necessity
because of poor relationships due to stigma, inaccessibil-
ity, and conflicts. Other research has shown that patients
may be more likely or willing to engage with pharmacy
services depending on how well pharmacists listened to
them in previous service encounters [57]. People are also
more likely to build and sustain relationships with
pharmacists when they are more satisfied about the
quality of care they receive [58]. Positive relationship
examples discussed by our participants were facilitated by
various characteristics including the absence of stigma
and judgment, sufficient time for discussion either in
person or over the phone, adequate privacy, and perceived
capabilities of the pharmacist. Lack of time and privacy
have been reported by others as barriers to patient
participation in education and consultations offered by
pharmacists [59].
Participants in our study also desired to have more time
and more access to be able to capitalize on the pharmacist’s
knowledge for decision-making about treatments, including
aspects such as whether a medication would be the correct
one based on research evidence and other treatment op-
tions. This is particularly important given that medication-
related information needs are not consistently addressed by
health care professionals [60, 61] and that an overall move-
ment in health care in recent decades is towards more
patient-centred care and patient involvement in decision-
making [62]. Patients can experience additional challenges
in deciphering the quality and relevance of information
among extensive quantities and types of health information
that currently exist through various means (e.g., Internet).
At times, patients may also lack awareness about what
needs to be asked in clinical encounters, which was identi-
fied in this study and has been previously identified in
youth with mental illness [63].
Participant PLEs shared information about their infor-
mation resource use including health databases (e.g.,
PubMed), medical libraries, Internet sites, journal
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articles, and other resources. They discussed knowledge
of evidence-based practice concepts and expressed
desires to have help with accessing, interpreting, and ap-
plying this information in their decision-making. Previ-
ous research demonstrates that various issues with
health literacy and numeracy can impact patients in
understanding and applying evidence-based and other
information in health care [64–67]. Satisfying PLEs’
information needs and facilitating decision support with
the help of pharmacists did not, and was unlikely, to
occur for many PLEs in our study given the nature of
discussions around lack of staffing, time, and privacy.
The PLEs in our study also expressed an interest in
having non-pharmacological alternatives (e.g., cognitive
behavioural therapy) as treatment options and they saw
pharmacists fulfilling roles in recommending other re-
sources (e.g., community groups) outside of medications.
Youth taking psychotropics have previously reported a
desire for alternatives beyond medications and disclosed
using a variety of interventions [68]. Other literature has
demonstrated that pharmacists who understand these
preferences and the patients’ perspectives on the mean-
ing of medication may be better at patient-centred
engagement and service provision [69].
For some patients, questioning medications, including
asking whether the medication is necessary and exploring
non-pharmacological therapies, may be a means of regain-
ing a sense of control in their life after illness and medica-
tions create a shift in the person’s identity [68, 69]. For
some PLEs, the act of taking psychotropics is viewed as an
essential component of care but simultaneously stigmatiz-
ing [68–70]. The experience of stigma and judgment
occurred and was feared by many of our participants lead-
ing to unnecessary emotional strain and alterations in
accessing pharmacists’ services. Several PLEs took decisive
action as a result of the experience of stigma by pharmacy
staff and switched to another pharmacy. In these examples,
stigma created emotional distress and frustration and led to
challenges in finding a new pharmacy and establishing
rapport and trust with another pharmacist. In other
research of community pharmacy-based mental illness and
addictions care in Canada and elsewhere, issues with
stigma, although still present [12, 13, 16, 19, 23, 24, 71–74],
may be on the decline with improved motivations and
increased capabilities of pharmacists in mental illness
and addictions care through the use of various inter-
ventions (e.g., education, training, enablement, modeling,
etc. [42]) [18, 20, 75, 76].
Finally, an important subtheme in our findings was the
notion of crises and triage by pharmacists, especially
around suicide, including by self-poisoning, which was
discussed by some of our participants. The research to
date on the topic of pharmacist assessment and mitiga-
tion of suicide is practically non-existent and urgently
requires attention [77], especially given trends regarding
suicide attempts and suicides, including the use of medi-
cations as a means for suicide [77–87]. Recent study
findings by Finkelstein et al. [87] highlight important
lessons for community pharmacists who may be in-
volved in the provision of medications that may be used
in some self-poisonings (both prescription and non-
prescription medications). Based on the data reported
[87], two in five people overall, and one in five teenagers,
died by overdose, after an initial self-poisoning episode
requiring hospital care. Many of these people likely
visited a pharmacy to obtain a medication for the treat-
ment of a psychiatric illness. Others whom may have
had a psychiatric illness would have visited a pharmacy
to obtain a medication for a concurrent medical disorder
(e.g., respiratory or cardiac disease, cancer, etc.). Thus, it
is highly probable that pharmacists encounter patients at
risk of suicide by self-poisoning and therefore a more
comprehensive approach is needed for education, train-
ing, and research related to pharmacists’ roles in suicide
risk assessment and mitigation [77].
Limitations
One interviewee, who passed the screening checklist as
community-dwelling, lived in a group home [88]. We
included this transcript in the analysis as the contribu-
tions made to themes were within the scope of our
study, but we also recognized that this group of PLEs
would benefit from their own study regarding their in-
teractions with pharmacists given their unique situation.
Based on the participants in our study, we are also not
able to make claims from our sample regarding substan-
tive findings that are for people specifically with addic-
tions (e.g., opioids or those receiving opioid replacement
treatment). Although findings and our themes (e.g.,
stigma) may resonate with available literature on those
with addictions, it is important to acknowledge this
boundary both within our data and findings.
Our convenience sampling and recruitment methods
may have led to a group of participants with a particular
bias or motivation for participating.
We cannot claim that our interpretation of the data
from individuals, in a specific context and health system,
is the only one that exists.
Conclusions
There are central elements to the experience of people with
lived experience of mental illness and addictions in acces-
sing and receiving community pharmacy services, which
include modified expectations, a desire for pharmacist sup-
port in treatment decision-making, and health and wellness
supports. Eight subthemes were identified including: rela-
tionships with pharmacy staff; patient’s role in the
pharmacist-patient relationship; crisis and triage; privacy
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and confidentiality; time; stigma and judgment; medication-
related and other services; and transparency. Research in
the area of pharmacists’ roles in crises and triage, and
especially suicide, is urgently needed. Future interventions
for pharmacists and pharmacy staff may include compo-
nents (e.g., education and training) to improve knowledge,
attitudes, and behaviours with respect stigma and suicide
risk assessment and mitigation. People with lived experi-
ence of mental illness and addictions have higher expecta-
tions of service delivery compared to what is often offered
but are willing to adjust expectations given constraints they
observe in community pharmacy practice.
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